Log in

NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, Forecast & News

$13.19
+0.20 (+1.54 %)
(As of 12/8/2019 10:49 AM ET)
Today's Range
$12.98
Now: $13.19
$13.58
50-Day Range
$9.92
MA: $11.56
$13.40
52-Week Range
$8.81
Now: $13.19
$15.33
Volume172,390 shs
Average Volume211,153 shs
Market Capitalization$323.16 million
P/E RatioN/A
Dividend YieldN/A
Beta1.06
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIGR
CUSIPN/A
Phone650-272-6138

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.49 per share

Profitability

Net Income$-52,390,000.00

Miscellaneous

Employees18
Market Cap$323.16 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.


Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

What is Eiger Biopharmaceuticals' stock symbol?

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

How were Eiger Biopharmaceuticals' earnings last quarter?

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) posted its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.75) by $0.01. View Eiger Biopharmaceuticals' Earnings History.

When is Eiger Biopharmaceuticals' next earnings date?

Eiger Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Eiger Biopharmaceuticals.

What price target have analysts set for EIGR?

6 brokers have issued 1-year price targets for Eiger Biopharmaceuticals' stock. Their forecasts range from $10.72 to $47.00. On average, they anticipate Eiger Biopharmaceuticals' share price to reach $31.62 in the next year. This suggests a possible upside of 139.7% from the stock's current price. View Analyst Price Targets for Eiger Biopharmaceuticals.

What is the consensus analysts' recommendation for Eiger Biopharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eiger Biopharmaceuticals.

What are Wall Street analysts saying about Eiger Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Eiger Biopharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. " (11/8/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "We believe its cash is sufficient to fund operations through profitability in 2022, assuming it nets ~$50M for its after splitting it with the Progeria Research Foundation. While the last four months the news flow from Eiger’s HDV and progeria programs has been quiet, the next four months include several catalysts in these programs." (8/12/2019)

Has Eiger Biopharmaceuticals been receiving favorable news coverage?

News stories about EIGR stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eiger Biopharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Eiger Biopharmaceuticals.

Who are some of Eiger Biopharmaceuticals' key competitors?

What other stocks do shareholders of Eiger Biopharmaceuticals own?

Who are Eiger Biopharmaceuticals' key executives?

Eiger Biopharmaceuticals' management team includes the folowing people:
  • Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 55)
  • Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 56)
  • Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 54)
  • Mr. James P. Shaffer, Chief Bus. Officer (Age 52)
  • Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 38)

Who are Eiger Biopharmaceuticals' major shareholders?

Eiger Biopharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (1.76%), Squarepoint Ops LLC (0.48%), Trellus Management Company LLC (0.35%), Tocqueville Asset Management L.P. (0.15%), California Public Employees Retirement System (0.06%) and Barclays PLC (0.06%). Company insiders that own Eiger Biopharmaceuticals stock include David A Cory, Eldon C Mayer III, Interwest Partners X Lp, Joanne Quan, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Institutional Ownership Trends for Eiger Biopharmaceuticals.

Which major investors are selling Eiger Biopharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Barclays PLC and California Public Employees Retirement System. View Insider Buying and Selling for Eiger Biopharmaceuticals.

Which major investors are buying Eiger Biopharmaceuticals stock?

EIGR stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Trellus Management Company LLC, Metropolitan Life Insurance Co NY, Lindbrook Capital LLC, Psagot Investment House Ltd. and Tocqueville Asset Management L.P.. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include David A Cory, Eldon C Mayer III, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Insider Buying and Selling for Eiger Biopharmaceuticals.

How do I buy shares of Eiger Biopharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eiger Biopharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $13.19.

How big of a company is Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals has a market capitalization of $323.16 million. The biotechnology company earns $-52,390,000.00 in net income (profit) each year or ($3.82) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe.View Additional Information About Eiger Biopharmaceuticals.

What is Eiger Biopharmaceuticals' official website?

The official website for Eiger Biopharmaceuticals is http://www.eigerbio.com/.

How can I contact Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]


MarketBeat Community Rating for Eiger Biopharmaceuticals (NASDAQ EIGR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  371 (Vote Outperform)
Underperform Votes:  259 (Vote Underperform)
Total Votes:  630
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Short Selling

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel